Claims
- 1. An antibody that binds to human SAF-2.
- 2. The antibody of claim 1 wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.
- 3. The antibody of claim 2, wherein the antibody is monoclonal antibody 2C4.
- 4. An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of claim 1.
- 5. An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of claim 2.
- 6. An isolated polypeptide comprising an immunoglobulin complementarity determining region of the antibody of claim 3.
- 7. An isolated polynucleotide encoding the polypeptide of claim 4.
- 8. An isolated polynucleotide encoding the polypeptide of claim 5.
- 9. An isolated polynucleotide encoding the polypeptide of claim 6.
- 10. The polypeptide of claim 6 wherein the immunoglobulin complementarity determining region that comprises the polypeptide is set forth in a member of the group consisting of SEQ ID NO:5, 6, 7, 8, 9 and 10.
- 11. The polypeptide of claim 10 wherein the immunoglobulin complementarity determining region comprises the polypeptides set forth in SEQ ID NOs:3, 4 and 5.
- 12. The polypeptide of claim 10 wherein the immunoglobulin complementarity determining region comprises the polypeptides set forth in SEQ ID NOs:6, 7 and 8.
- 13. An isolated polynucleotide encoding the polypeptide of claim 10.
- 14. An isolated polynucleotide encoding the polypeptide of claim 11.
- 15. An isolated polynucleotide encoding thc polypeptide of claim 12.
- 16. The antibody of claim 1 wherein the immunoglobulin complementarity determining region of the antibody comprises the polypeptides set forth in SEQ ID NO:5, 6, 7, 8, 9 and 10.
- 17. The antibody of claim 16 comprising a heavy chain variable region polypeptide as set forth in SEQ ID NO:2 and a kappa light chain variable region polypeptide as set forth in SEQ ID NO:4.
- 18. An isolated polynucleotide encoding a polypeptide comprising a member selected from the group consisting of SEQ ID NO:2 and SEQ ID NO:4.
- 19. A hybridoma cell line that produces a monoclonal antibody having the identifying characteristics the monoclonal antibody 2C4.
- 20. A pharmaceutical composition comprising the antibody of claim 1.
- 21. A pharmaceutical composition comprising the antibody of claim 2.
- 22. A pharmaceutical composition comprising the monoclonal antibody of claim 3.
- 23. A method for detecting the presence of a cell in a sample wherein the cell comprises an SAF-2 protein, the method comprising:
a) exposing the sample to an antibody that binds to SAF-2; and b) detecting the antibody that is bound to SAF-2.
- 24. The method of claim 23 wherein the sample is treated before exposure to the antibody such that the SAF-2 protein is accessible to binding by the antibody.
- 25. The method of claim 23 wherein the cell is a member selected from the group consisting of an eosinophil, a basophil and a mast cell.
- 26. The method of claim 23 wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.
- 27. The method of claim 26 wherein the antibody is monoclonal antibody 2C4.
- 28. A method for altering the function or viability of a cell expressing SAF-2 comprising contacting the cell with a therapeutic agent that binds to SAF-2.
- 29. The method of claim 28 wherein the cell is selected from the group consisting of eosinophils, basophils and mast cells.
- 30. The method of claim 28 wherein the therapeutic agent is an antibody.
- 31. The method of claim 28 wherein contact with the therapeutic agent induces apoptosis of the cell.
- 32. A method for preventing or treating a disease or condition mediated by cells expressing SAF-2, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising a therapeutic agent that binds to SAF-2.
- 33. The method of claim 32 wherein the disease is an allergic, asthmatic or cancerous disease or a hypereosinophilic syndrome.
- 34. The method of claim 33 wherein the disease is a member selected from the group consisting of asthma, allergic rhinitis, atopic dermatitis, chronic urticaria, nasal polyposis, Churg-Strauss Syndrome, allergic bronchopulmonary Aspergillosis or eosinophilic leukemia, eczema, systemic mastocytosis, lymphoma, eosinophilic leukemia and basophilic leukemia.
- 35. The method of claim 32 wherein the therapeutic agent is an antibody.
- 36. The method of claim 35 wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.
- 37. The method of claim 32 wherein the pharmaceutical composition further comprises a cytokine.
- 38. The method of claim 37 wherein the cytokine is a member selected from the group consisting of IL-5 and GM-CSF.
- 39. A pharmaceutical composition comprising an effective amount of a therapeutic agent that binds to SAF-2.
- 40. The pharmaceutical composition of claim 39 wherein the therapeutic agent is an antibody.
- 41. The pharmaceutical composition of claim 40 wherein the antibody has the identifying characteristics of monoclonal antibody 2C4.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part of application of PCT International Application No. PCT/US01/07193, filed Mar. 5, 2001, now pending, which claims benefit of U.S. Provisional Application No. 60/187,595, filed Mar. 7, 2000, now abandoned. This continuation-in-part application also claims the benefit of U.S. Provisional Application No. 60/315, 943, filed Aug. 30, 2001, now pending, 60/349,830, filed Jan. 18, 2002, now pending, and No. 60/394,741, filed Jul. 10, 2002, now pending.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] This invention resulted from research funded in whole or in part by the National Institutes of Health, Grant No. A141472. The Federal Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60187595 |
Mar 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/07193 |
Mar 2001 |
US |
Child |
10232187 |
Aug 2002 |
US |